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differences fitted within our ±5-point margin of equivalence. 
 Results: Except for a higher socioeconomic status of the trial 
participants, both groups were balanced for most perinatal 
variables. The mean difference (90% CI) between the eligible 
NR and the placebo group was –2.1 (–6.1 and 1.9) points for 
the MDI and –0.8 (–4.2 and 2.5) points for the PDI. After ad-
justing for the socioeconomic status, maternal age and child 
age at follow-up, the mean difference for the MDI was –0.5 
(–4.3 and 3.4) points.  Conclusions: Our results indicate that 
the participation of very preterm infants in an RCT is associ-
ated with equivalent long-term outcomes compared to non-
participating infants.  © 2014 S. Karger AG, Basel 
 Introduction 
 Sixty-five years ago, the implementation of random-
ized controlled trials (RCT) ushered in a new era of med-
ical research  [1] . This type of scientific experiment has 
since been accepted as the gold standard for clinical trials 
and the most reliable method for evidence-based deci-
sion-making  [2, 3] . For approximately the same period, 
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 Abstract 
 Background: Since the introduction of randomized con-
trolled trials (RCT) in clinical research, there has been discus-
sion of whether enrolled patients have worse or better out-
comes than comparable non-participants.  Objective: To in-
vestigate whether very preterm infants randomized to a 
placebo group in an RCT have equivalent neurodevelop-
mental outcomes to infants who were eligible but not ran-
domized (eligible NR).  Methods: In the course of an RCT in-
vestigating the neuroprotective effect of early high-dose 
erythropoietin on the neurodevelopment of very preterm 
infants, the outcome data of 72 infants randomized to pla-
cebo were retrospectively compared with those of 108 eli-
gible NR infants. Our primary outcome measures were the 
mental (MDI) and psychomotor (PDI) developmental indices 
of the Bayley Scales of Infant Development II at 24 months of 
corrected age. The outcomes of the two groups were consid-
ered equivalent if the confidence intervals (CIs) of their mean 
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there has been widespread discussion about whether en-
rolled patients have worse or better outcomes than com-
parable non-participants. On the one hand, critical voices 
emphasize the potential risks to which patients are ex-
posed when participating in a clinical trial. On the other 
hand, an increasing number of researchers and patients 
believe that participating in clinical research is neither 
risky nor dangerous but beneficial and desirable instead. 
However, there is limited evidence that such a positive 
‘trial effect’ exists.
 Previous research comparing the patient outcomes 
within and outside an RCT has largely focused on adults 
 [4–6] . Although these studies varied in their conclusions, 
they all found that participating in a clinical trial more 
likely results in positive than negative effects. A major 
disadvantage of most of these systematic reviews is that 
they compared all patients who were treated in the trials 
with all patients who were not enrolled, regardless of the 
clinical intervention performed or differences in the pa-
tient populations. Consequently, the results are potential-
ly influenced by a selection bias and at least two (i.e. treat-
ment and protocol effect) of the five components that po-
tentially favor clinical trials ( table 1 )  [6] .
 In light of the sparse data available about a trial effect 
in preterm infants and no available data about its long-
term effects, the objective of this study was to investigate 
whether very preterm infants enrolled in a clinical trial 
and randomized to placebo treatment have neurodevel-
opmental outcomes that are equivalent to those of infants 
who were eligible but not randomized (eligible NR).
 Methods 
 Our study group consisted of very preterm infants between 
26 0/7 and 31 6/7 gestational weeks who were enrolled in an RCT 
lasting from September 2005 to January 2011 (www.clinicaltrials.
gov; NCT00413946)  [7] . The primary objective of this clinical 
trial was to determine whether the neurodevelopmental out-
comes are improved in very preterm infants when they are ad-
ministered early high-dose erythropoietin (EPO). Infants were 
excluded for any of the following reasons: born outside of a peri-
natal center, genetically defined syndromes, severe congenital 
malformations adversely affecting life expectancy or neurodevel-
opment, and infants who were a priori admitted for palliative 
care. Within the first 3 h of life, the infants were randomized to 
receive EPO or placebo (NaCl 0.9%) intravenously at 3, 12–18, 
and 36–42 h after birth. Other than the study treatment, all pro-
cedures and examinations were standard practice of care. At 24 
months of age (corrected for prematurity), the mental and psy-
chomotor development was assessed using the Bayley Scales of 
Infant Development II  [8] . Of all infants enrolled in the EPO tri-
al, only the infants born at our perinatal center and randomized 
to placebo were eligible for the present analysis. The infants with 
incomplete follow-up data at 2 years of age were excluded.
 Our control group was restricted to concurrent preterm infants 
born at our perinatal center who would have met the eligibility 
criteria for the EPO trial. They were not enrolled in the EPO trial 
for any of the following reasons: failure to obtain parental consent, 
parents were not approached, language barriers, and failure to ob-
tain written informed consent because of an emergency. Of the 
remaining infants, those with incomplete follow-up data at 2 years 
of age were excluded. Data on these eligible NR controls were col-
lected prospectively and entered into a large database maintained 
by the Swiss Neonatal Network & Follow-Up Group. Socioeco-
nomic status (SES) was estimated based on paternal occupation 
and maternal education  [9] . The scores ranged from 2 (highest 
SES) to 12 (lowest SES). Our primary outcome measures were the 
mental (MDI) and psychomotor (PDI) developmental indices of 
the Bayley Scales of Infant Development II at 24 months of cor-
rected age.
 Ethics 
 The EPO trial was approved by the Ethical Committee of the 
Canton Zurich and by Swissmedic in Bern. Written informed con-
sent was obtained from the parents of infants in the placebo group, 
ideally before birth. The parents of the eligible NR infants did not 
object that data from their infants would be used for scientific anal-
ysis after anonymization.
 Statistics 
 Comparisons between groups were based on the Mann-Whit-
ney test for continuous variables and the Fisher’s exact test for 
nominal variables.
 An equivalence test regarding the two primary outcomes was 
performed  [10, 11] . The aim of such a test is to show that the two 
groups of interest do not differ by more than a prespecified margin 
of clinical relevance. This is different from classical superiority 
testing, where the aim is to show that the two groups differ. To 
perform an equivalence test at the level of 5%, a 90% confidence 
interval (CI) is constructed for the mean difference between the 
outcomes in the two groups. Equivalence is shown if the whole in-
terval is between –Δ and Δ. As the width of the CI plays a crucial 
role here, we assessed the sample size with reference to precision 
rather than power.
 Table 1.  Components of the trial effect
Trial effect Differences
Treatment effect Treatment offered in a study is better than 
the current standard of care
Protocol effect Strict adherence to well-defined protocols
Care effect More extensive follow-up or nursing care
Hawthorne effect Changes in patient or clinician behavior as
a result of being under close observation in
a trial
Placebo effect Psychologically mediated benefits associated 
with the administration of a sham or 
simulated intervention
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 We set the margin of clinical relevance at Δ = 5 points (0.3 stan-
dard deviations of the Bayley Scales of Infant Development II). We 
constructed unadjusted CIs based on the t test, as well as CIs ad-
justed for potential confounders based on linear regression. The 
sample size assessment was based on the assumption that the stan-
dard deviation of both MDI and PDI is 15 points. From the EPO 
trial, there were 83 infants in the placebo group and 193 eligible 
NR infants available ( fig. 1 ). These sample sizes achieve a 90% CI 
for the unadjusted group difference of width 6.5 points (i.e. ap-
proximately two thirds of the width of the range between –5 and 
5). This was considered to be sufficiently accurate, even after the 
possible exclusion of some infants due to loss to follow-up or 
death.
 Results 
 A total of 180 infants born at our perinatal center were 
included in this study: 72 infants from the placebo group 
of the EPO trial, and 108 eligible but NR infants ( fig. 1 ). 
The perinatal variables were evenly distributed, but SES 
and maternal age was higher in the placebo group com-
pared to the eligible NR group ( table 2 ).
 The short-term outcome until discharge was similar in 
the two groups ( table 3 ), but the eligible NR infants suf-
fered more often from a low-grade intraventricular hem-
orrhage (IVH – grade I and II) than those infants ran-
domized to placebo.
 The follow-up rate at 2 years of age differed signifi-
cantly between the two groups (placebo 92.3%, eligible 
NR 62.1%, p < 0.001). The demographics and short-term 
outcomes of the eligible NR infants with (n = 108) and 
without (n = 66) follow-up examinations are given in  ta-
ble 4 , showing an increased rate of low-grade intraven-
tricular hemorrhages and a trend towards a higher SES in 
the group of infants who were examined.
 At the follow-up examination, the mean age ± stan-
dard deviation was 22.9 ± 1.7 months in the placebo 
group and 23.7 ± 2.4 months in the eligible NR group 
(p < 0.001). Neither the placebo nor eligible NR groups 
showed a significantly increased incidence of visual (p = 
0.49) or hearing (p = 0.40) problems, and the rate of in-
fants receiving physical, occupational or child psychiatry 
therapy (p = 0.51) was similar.
440 candidates for EPO trial during study period
80 excluded
 - 35 had dysmorphic features or
  congenital abnormalities likely
  to affect life expectancy or
  neurologic development
 - 1 was unlikely to be available for
  long-term follow-up
 - 26 took part in another clinical trial
 - 18 for unknown reasons
360 infants eligible
193 did not undergo randomization
 - 83 not approached
 - 72 consent not obtained
 - 20 emergency situations
 - 18 language barriers
EPO trial – placebo
83 cases
EPO trial – verum
84 cases
Placebo
72 cases
Eligible not randomized
108 cases
11 excluded
 - 5 died
 - 6 no follow-up
85 excluded
 - 19 died
 - 66 no follow-up
 Fig. 1. Number of infants who were eligible 
for the study. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
6/
3/
20
16
 2
:5
8:
13
 P
M
 Randomized Controlled Trials in Very 
Preterm Infants 
 Neonatology 2014;106:114–119 
DOI: 10.1159/000362784
117
 Our primary outcomes did not differ significantly be-
tween the two groups, but the unadjusted 90% CI of the 
mean MDI difference was –6.1 and 1.9 points (mean dif-
ference –2.1 points) and exceeded our margins of equiva-
lence in favor of the infants in the placebo group ( fig. 2 ). 
After adjusting for SES, maternal age, and child age at 
follow-up, the 90% CI of the mean MDI difference was 
within our predefined ±5-point margin of equivalence. 
The unadjusted 90% CI of the mean PDI difference was 
–4.2 and 2.6 points (mean difference –0.8 points) and did 
not materially change after the adjustment for SES, ma-
ternal age, and child’s age at follow-up.
 We also analyzed whether other perinatal risk factors 
were related to our primary outcomes. At 2 years of age, 
none of them had a significant impact on either MDI or 
PDI.
 Discussion 
 The long-debated theory of a trial effect led us to infer 
that preterm infants enrolled in an RCT and randomized 
to placebo would have the same long-term outcomes than 
eligible NR controls. Our findings confirm this theory, as 
the participation in the placebo arm of the EPO trial was 
associated with equivalent long-term outcomes to receiv-
ing the same treatment outside the trial.
 To date, only one study investigating a potential trial 
effect on the short-term outcome of very preterm infants 
has been performed  [12] . First, the authors found a re-
duction in the median duration of mechanical ventilation 
from 6.2 days in the eligible NR group to 4.8 days in the 
placebo group (p = 0.008). Second, there was also a trend 
toward less frequent and less severe IVH in the trial par-
ticipants. They concluded that sick newborns might ben-
efit from participation in a RCT and speculated that a 
protocol effect and possibly the scrutiny from study per-
sonnel may have benefited infants in the placebo arm of 
the trial.
 Table 2.  Baseline characteristics
Characteristics Placebo
(n = 72)
Eligible NR
(n = 108)
p 
value
Pregnancy complicationsa 34/72 (47.2) 46/108 (42.6) 0.54
Prenatal steroids 66/72 (91.7) 97/104 (93.3) 0.77
Male gender 43/72 (59.7) 53/108 (49.1) 0.17
Gestational age, weeks 29.5 ± 1.5 29.5 ± 1.7 0.84
Birth weight, g 1,236 ± 354 1,222 ± 335 1.00
Head circumference at 
birth, cm 27.3 ± 2.3 27.0 ± 2.2 0.61
Umbilical artery pH 7.33 ± 0.1 7.31 ± 0.1 0.36
Socioeconomic status score 5.2 ± 2.3 6.0 ± 2.7 0.04
Maternal age, years 33.1 ± 6.0 31.1 ± 5.7 0.03
Values are n (%) or means ± SD. a Chorioamnionitis, gesta-
tional diabetes, preeclampsia or HELLP syndrome.
 Table 3.  Short-term outcome until discharge
Outcome measures Placebo
(n = 72)
Eligible NR
(n = 108)
p 
value
Mechanical ventilation, days 1.4 ± 2.6 0.9 ± 1.7 0.12
CPAP treatment, days 11.2 ± 14.8 10.3 ± 14.1 0.68
Supplemental oxygen, days 21.3 ± 24.3 15.5 ± 21.5 0.12
LOS of the survivors, days 55.0 ± 19.8 56.0 ± 25.7 0.69
Surfactant 24/72 (33.3) 33/108 (30.6) 0.74
IVH I and II 5/72 (6.9) 28/108 (25.9) 0.001
IVH III and IV 4/72 (5.6) 6/108 (5.6) 1.00
Sepsis 11/72 (15.3) 16/108 (14.8) 1.00
ROP 1 – 4 4/70 (5.7) 8/94 (8.5) 0.56
Necrotizing enterocolitis 4/72 (5.6) 4/107 (3.7) 0.72
BPD 1 – 3 9/72 (12.5) 10/106 (9.4) 0.62
Values are means ± SD or n (%). LOS = Length of stay; ROP = 
retinopathy of prematurity; BPD = bronchopulmonary dysplasia. 
 Table 4.  Demographics and short-term outcomes of the eligible 
NR infants with and without follow-up examinations
Outcome measures  Eligible NR p 
valuewit h follow-up
(n = 108)
without follow-
up (n = 66)
Socioeconomic status score 6.0 ± 2.7 6.7 ± 2.3 0.06
Maternal age, years 31.1 ± 5.7 31.5 ± 6.2 0.78
Mechanical ventilation, days 0.9 ± 1.7 1.5 ± 4.8 0.85
CPAP treatment, days 10.3 ± 14.1 8.5 ± 12.4 0.54
Supplemental oxygen, days 15.5 ± 21.5 16.3 ± 20.2 0.45
LOS of the survivors, days 56.0 ± 25.7 51.5 ± 19.6 0.33
Surfactant 33/108 (30.6) 16/66 (24.2) 0.39
IVH I and II 28/108 (25.9) 7/66 (10.6) 0.02
IVH III and IV 6/108 (5.6) 2/66 (3.0) 0.71
Sepsis 16/108 (14.8) 7/66 (10.6) 0.50
ROP 1 – 4 8/94 (8.5) 5/52 (9.6) 1.00
Necrotizing enterocolitis 4/107 (3.7) 1/66 (1.5) 0.65
BPD 1 – 3 10/106 (9.4) 3/65 (4.6) 0.37
 Values are means ± SD or n (%). LOS = Length of stay; ROP = 
retinopathy of prematurity;BPD = bronchopulmonary dysplasia. 
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 Our short-term outcomes were similar in both groups, 
except for the rate of low-grade IVHs. These bleedings can 
be difficult to identify  [13] and might, therefore, be par-
ticularly sensitive to over- or underdiagnosing. An in-
creased diagnostic quality based on an independent and 
blinded panel of experts supervising the correct grading of 
IVHs within an RCT might be the cause for the reported 
differences between the placebo and the eligible NR group.
 Our main results aligned with those of the most recent 
published studies  [14–16] , although the concept of an ‘in-
clusion benefit’ differs in various ways between well-in-
formed adults and very preterm infants. First, in addition 
to the study treatment, all procedures were the same in 
our placebo and eligible NR groups. An advantage arising 
from a better experimental treatment within the trial 
(treatment effect) can, therefore, be ruled out. Second, the 
treatment of very preterm infants in our neonatal inten-
sive care unit is already largely standardized. Therefore, 
adhering to rigorous treatment guidelines, as outlined in 
a clinical trial (protocol effect), would not likely add value 
in such an already strictly controlled setting. Third, most 
neonatal intensive care units follow the policies of ‘mini-
mal handling’ attempting to limit the number of inter-
ventions and their routine periodicity, which goes against 
the idea that trial participants might benefit from extra 
nursing cover or any additional examinations (care ef-
fect). Furthermore, our trial protocol did not require 
more comprehensive care for the randomized infants. Fi-
nally, there is little chance of intrinsic trial effects in very 
preterm infants.
 For all these reasons, our main findings argue against 
a long-lasting trial effect in the most immature infants. 
However, we appreciate that parents, clinicians, and 
nurses may likewise develop placebo or Hawthorne ef-
fects that may result in altered decision-making. Further 
bias might arise from differences between parents who 
authorize the participation of their infant in an RCT and 
non-consenting parents. Our data confirm these subtle 
but important differences, as parents with a higher SES 
were more likely to allow participation of their infant in 
our trial. This finding is important because SES has also 
been the strongest confounder for the mental outcome, 
increasing the MDI by 2.0 points on average (95% CI 2.9 
and 1.1) for every point towards a higher SES.
 The variables SES, mother’s age and child’s age at fol-
low-up were significantly imbalanced between the pla-
cebo and the eligible NR groups and at the same time, 
clinically relevant in terms of our primary outcomes. 
Consequently, all three variables were included in our lin-
ear regression models to eliminate bias from the analysis. 
Nevertheless, it remains unclear why the infants in the 
placebo group were significantly younger at follow-up.
 Although such examinations at 2 years of corrected 
age are standard practice of care for all very low birth 
weight infants in Switzerland, there was a higher ‘lost to 
follow-up’ rate in the eligible NR group than in the pla-
cebo group. This difference alone is a significant finding, 
as better follow-up leads to earlier detection of develop-
mental problems and, consequently, earlier initiation of 
therapeutic strategies. However, structured follow-up 
programs for premature infants are not yet implemented 
in all countries and exclusion from such preventive mea-
sures will more likely result in negative effects for infants 
who do not participate in the trial. Given that the infants 
within and outside the trial receive the same or similar 
treatment, it can likewise be stated that non-participation 
was not correlated with an adverse outcome. This result 
is of particular interest for all parents who are concerned 
about any potential negative consequences for their pre-
term infant when refusing trial participation.
Variable Adjusted for Favors placebo ↔ Favors eligible NR Effect size (90% CI)
MDI –2.1 (–6.1, 1.9)
SES, maternal age,
age at follow-up –0.5 (–4.3, 3.4)
PDI –0.8 (–4.2, 2.5)
SES, maternal age,
age at follow-up –0.6 (–4.1, 2.9)
Mean difference with 90% CI; margins of equivalence at ±5 points
–6 –4 –2 0 2 4 6
 Fig. 2. Non-adjusted and adjusted long-term outcomes. 
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 Our study is strengthened by the following factors: (1) 
using appropriate comparison groups in which the trial 
patients differed from the non-trial patients in exposure 
to three doses of NaCl 0.9% only; (2) equally distributing 
at baseline for the most important prognostic factors; (3) 
adjusting our primary outcomes for the parental SES, ma-
ternal age, and infants’ age at follow-up, and (4) evaluating 
the trial effect on a long-term basis. The main limitations 
of this study relate to its retrospective design and to the 
lack of complete datasets at the 2-year follow-up examina-
tion for some infants. This loss to follow-up bias is a major 
drawback of all long-term follow-up studies and results in 
unclear consequences for the remaining study population 
 [17–19] . In addition, there is increasing evidence that 
2-year outcome assessments in very preterm infants might 
be limited in predicting later cognitive functions  [20] .
 In conclusion, we found additional evidence to sup-
port our hypothesis that trial participation of very pre-
term infants allocated to a placebo group is associated 
with an equivalent long-term outcome compared to con-
current nonparticipants. In addition to and regardless of 
any benefits, parents can be told that neither trial partici-
pation nor non-participation is related to any harmful or 
negative effects given that the infants within and outside 
the trial receive the same or similar treatment.
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